AI assistant
Applied Therapeutics, Inc. — Director's Dealing 2024
Dec 21, 2024
34263_dirs_2024-12-20_b6473e50-ab8a-4ee7-80f6-5002a51c5898.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Applied Therapeutics, Inc. (APLT)
CIK: 0001697532
Period of Report: 2024-12-19
Reporting Person: Funtleyder Leslie D. (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-12-19 | Common Stock | A | 150000 | — | Acquired | 427911 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-12-19 | Stock Option (Right to Buy) | $1.02 | A | 150000 | Acquired | 2034-12-19 | Common Stock (150000) | Direct |
Footnotes
F1: Consists of compensatory Restricted Stock Units ("RSUs") granted under Applied Therapeutics, Inc.'s 2019 Equity Incentive Plan (the "Plan") in connection with the Reporting Person's service as interim Chief Executive Officer. Each compensatory RSU represents a contingent right to receive one share of the issuer's common stock. The compensatory RSUs will vest in equal monthly installments over the 12-month period following the grant date, subject to the Reporting Person continuing to provide services through each such vesting date, provided that any outstanding and unvested RSUs will vest immediately upon the earlier to occur of (i) the approval by the United States Food and Drug Administration of the issuer's proposed new drug application relating to the treatment of Sorbitol Dehydrogenase or (ii) a Change in Control (as defined in the Plan).
F2: Consists of Options granted under the Plan in connection with the Reporting Person's service as interim Chief Executive Officer. The Options will vest in equal monthly installments over the 12-month period following the grant date, subject to the Reporting Person continuing to provide services through each such vesting date, provided that any outstanding and unvested Options will vest immediately upon the earlier to occur of (i) the approval by the United States Food and Drug Administration of the issuer's proposed new drug application relating to the treatment of Sorbitol Dehydrogenase or (ii) a Change in Control (as defined in the Plan).